- Home
- UTHR vs LECO Comparison
UTHR vs LECO Comparison
Compare UTHR & LECO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTHR
- LECO
- Stock Information
- Founded
- UTHR 1996
- LECO 1895
- Country
- UTHR United States
- LECO United States
- Employees
- UTHR N/A
- LECO N/A
- Industry
- UTHR Biotechnology: Pharmaceutical Preparations
- LECO Industrial Machinery/Components
- Sector
- UTHR Health Care
- LECO Industrials
- Exchange
- UTHR Nasdaq
- LECO Nasdaq
- Market Cap
- UTHR 13.8B
- LECO 13.4B
- IPO Year
- UTHR 1999
- LECO N/A
- Fundamental
- Price
- UTHR $312.23
- LECO $245.25
- Analyst Decision
- UTHR Buy
- LECO Buy
- Analyst Count
- UTHR 13
- LECO 8
- Target Price
- UTHR $382.00
- LECO $234.63
- AVG Volume (30 Days)
- UTHR 762.5K
- LECO 351.3K
- Earning Date
- UTHR 07-30-2025
- LECO 07-31-2025
- Dividend Yield
- UTHR N/A
- LECO 1.26%
- EPS Growth
- UTHR 17.94
- LECO 0.60
- EPS
- UTHR 25.63
- LECO 8.90
- Revenue
- UTHR $3,077,800,000.00
- LECO $4,098,850,999.00
- Revenue This Year
- UTHR $14.37
- LECO $4.07
- Revenue Next Year
- UTHR $6.59
- LECO $4.43
- P/E Ratio
- UTHR $12.18
- LECO $27.56
- Revenue Growth
- UTHR 17.62
- LECO 0.10
- 52 Week Low
- UTHR $266.98
- LECO $161.11
- 52 Week High
- UTHR $417.82
- LECO $246.83
- Technical
- Relative Strength Index (RSI)
- UTHR 58.33
- LECO 63.45
- Support Level
- UTHR $303.59
- LECO $236.52
- Resistance Level
- UTHR $317.31
- LECO $241.72
- Average True Range (ATR)
- UTHR 7.91
- LECO 4.64
- MACD
- UTHR 0.90
- LECO -0.91
- Stochastic Oscillator
- UTHR 80.53
- LECO 88.20
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
About LECO Lincoln Electric Holdings Inc.
Lincoln Electric is a leading manufacturer of welding, cutting, and brazing products. Its portfolio includes arc-welding solutions, plasma and oxy-fuel cutting systems, and brazing and soldering alloys, as well as automation solutions. Lincoln Electric serves clients in the general fabrication, heavy industries, automotive, construction, shipbuilding, energy, and process industries, among other end markets. Based in Cleveland, Lincoln Electric has operations in 19 countries and has 11,000 employees worldwide. The company generated roughly $4 billion in sales in 2024.